Western Financial Corp CA Makes New $741,000 Investment in Boston Scientific Co. (NYSE:BSX)

Western Financial Corp CA purchased a new stake in Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,291 shares of the medical equipment provider’s stock, valued at approximately $741,000.

Other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. acquired a new stake in Boston Scientific in the third quarter valued at about $28,000. Dunhill Financial LLC lifted its holdings in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 152 shares during the last quarter. Global Wealth Strategies & Associates boosted its stake in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new position in Boston Scientific during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $102.40 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52 week low of $62.63 and a 52 week high of $104.25. The firm has a 50 day moving average of $93.47 and a 200-day moving average of $86.21. The company has a market cap of $150.92 billion, a price-to-earnings ratio of 84.63, a price-to-earnings-growth ratio of 2.69 and a beta of 0.80.

Analysts Set New Price Targets

A number of brokerages have weighed in on BSX. TD Cowen raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. BTIG Research boosted their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Mizuho upped their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Raymond James lifted their price target on Boston Scientific from $101.00 to $119.00 and gave the company a “strong-buy” rating in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $98.35.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.